Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.15B P/E - EPS this Y -173.30% Ern Qtrly Grth -
Income -143.01M Forward P/E -4.76 EPS next Y -17.90% 50D Avg Chg -12.00%
Sales 352.57M PEG 1.44 EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 2.68 EPS next 5Y -3.70% 52W High Chg -61.00%
Recommedations 2.20 Quick Ratio 5.69 Shares Outstanding 82.42M 52W Low Chg 3.00%
Insider Own 1.50% ROA -8.82% Shares Float 64.45M Beta 1.85
Inst Own 93.45% ROE -17.17% Shares Shorted/Prior 10.96M/11.18M Price 28.25
Gross Margin -16.85% Profit Margin -40.56% Avg. Volume 846,674 Target Price 50.54
Oper. Margin -891.06% Earnings Date Nov 6 Volume 1,381,752 Change -0.91%
About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc. News
11/12/24 Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
11/07/24 Beam Therapeutics upgraded to Outperform from Market Perform at Leerink
11/06/24 Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
11/06/24 Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations
11/06/24 Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ...
11/06/24 Q3 2024 Beam Therapeutics Inc Earnings Call
11/05/24 Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
11/05/24 Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
11/05/24 Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
11/05/24 Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
11/05/24 Sickle cell patient dies in Beam study of base editing therapy
10/31/24 Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology
10/30/24 CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
10/29/24 Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
10/28/24 We're Interested To See How Beam Therapeutics (NASDAQ:BEAM) Uses Its Cash Hoard To Grow
10/23/24 Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine
10/17/24 State Street Corp's Strategic Acquisition in Beam Therapeutics Inc
09/05/24 Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?
08/14/24 Beam Therapeutics Inc. (BEAM): Pioneering Genetic Medicine with CRISPR Technology
08/09/24 3 Gene Editing Stocks with Potential to Transform Medicine
BEAM Chatroom

User Image 777Dog Posted - 35 minutes from now

$EDIT Two million shares will be bought and sold among Algo friends today...500k sold (dumped) in the first hour, followed by leveling off and buying back at a slightly lower average price...maybe even rise a penny or two up from the bottom at the close...1-5% down and retail will sound surprised... Stop buying...this is a sick joke being played on retail.... $EDIT, $PRME, $NTLA and possibly $BEAM will be variations on the theme... Then one day, somebody will change the Algo...that will be the buy signal for anybody paying attention....

User Image fubotvfan Posted - 21 hours ago

$NTLA Can somebody explain the stock performance difference bewteen $NTLA and $BEAM ? To me, $NTLA obviously did better on the pipline but the stock performance is much worse than $BEAM in the past 12 months.

User Image StockBillionaire2112 Posted - 2 days ago

$BEAM did it bottom out?

User Image Acadia2001 Posted - 2 days ago

$NTLA buying again under 13.5 my average is 15.25 πŸ™„ $BEAM adding more today under $24 , average is 24.5

User Image The_Harmonist Posted - 5 days ago

$BEAM looks promising just waiting for ASH.

User Image StockBillionaire2112 Posted - 5 days ago

$BEAM with some luck we can load up the truck again around 21-22 next week…

User Image DNAedit Posted - 5 days ago

$VERV is Base editing toast? $Beam and Verve are dropping big.

User Image DNAedit Posted - 5 days ago

$BEAM Ouch. Any news?

User Image BarneyR Posted - 5 days ago

$BEAM Sold at $27.50, wasn't about to ride this back to 22. Long term big potential but short term pain due to the uncertainty brought on by a unpredictable crazy person.

User Image glenwoodnate Posted - 6 days ago

$RXRX $SDGR $TEM $BEAM $VKTX Well, I guess the only positive thing one could say about the biotech sector is that it's had worse days. I'm still well above my entry points, but that was a pretty brutal sell-off. It makes me wonder whether there are circulating rumors about RFK Jr.

User Image Blizzy Posted - 1 week ago

$BEAM just bought another 200 shares. Average is now $40 x 750 shares. Holding for better days ahead πŸ‘ŒπŸΌπŸŽ±β³β³πŸ€žπŸΌ

User Image KHG1962 Posted - 1 week ago

$BEAM On Monday $BEAM went 17% up at one point - maybe because of the patent thing in Europe? No clue. I sold some. Will buy back lower, good to average down these wild swings.

User Image BarneyR Posted - 1 week ago

$CRSP $BEAM $NTLA $CRBU $VERV Been waiting for interest rates to come down. The market started to reward our patience with the promise of lower interest rates. Hold on, Barrons and other outlets were called to sound the alarm about Trump's plans and how it'll slow down Fed actions, make them think twice. Thanks Donny, we can see what a great affect you're going to have on the economy. Let's make sure you talk more about deporting our labor workforce, implementing cross the board tariffs and spiking the debt ceiling with corporate tax cuts. Those who voted you in will be the first and most affected. Hard lessons on the way. Look at what happened to the market today, and all they said was how Trump's plans might affect the fed. No one mentioned recession. There's a long way to fall if markets get jittery.

User Image BarneyR Posted - 1 week ago

$BEAM 320,000 shares traded premarket with a half hour til open? On a normal day, it'd be 320 shares. What's up with that?

User Image BarneyR Posted - 1 week ago

$BEAM Hey Pino, your patience would have been rewarded if you'd waited 4 weeks to sell shares. We'd probably be in the mid 30s today.

User Image Blizzy Posted - 1 week ago

$BEAM wow, what happened!!!??? πŸ‘πŸ»πŸ’΅πŸ”₯πŸ†πŸš€

User Image HarryScrotmsRashy Posted - 1 week ago

$BEAM Come on fly through $30.

User Image Jchoi0507 Posted - 1 week ago

$BEAM

User Image HarryScrotmsRashy Posted - 1 week ago

$BEAM This one seems to be working right back. Looks bullish. Hopefully we break through to the 30's.

User Image StockBillionaire2112 Posted - 1 week ago

$BEAM back to 22 next week only to pop back to 26-27 few weeks later. Free money every month!

User Image JG101 Posted - 2 weeks ago

$ATNM This one death in the $BEAM study from pre engraftment conditioning shows how primitive and dangerous old conditioning drugs are. All cell and gene therapy companies that need to administer pre conditioning drugs to their patients have this same issue. Actinium has an amazing drug to solve this issue. The picks and shovel play in the cell and gene therapy field… https://medcitynews.com/2024/11/gene-therapy-base-editing-beam-therapeutics-sickle-cell-disease-scd/

User Image Rumponstiffskin Posted - 2 weeks ago

$BEAM $SRPT $BLUE $NTLA $CRSP RFK run the FDA ? Is his brainworm doing the testing ? πŸ˜†

User Image Finanz Posted - 2 weeks ago

$BEAM Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $39.00 price target on the stock, up previously from $27.00 representing a 50% upside from the current price of $26.00.

User Image Stocksrunner Posted - 2 weeks ago

$BEAM Beam has garnered attention with analyst interest, but resistance at $26.64 is in focus. Breaking this level could drive further upside for this biotech stock.

User Image mikeg1999 Posted - 2 weeks ago

$CRSP $NTLA $SRPT $BEAM $BLUE i foresee the new executive branch supporting curative, transformative (key word PREVENTATIVE) therapeutic developments like gene therapies, while protein-based therapies (REACTIVE, profiting off of disease rather than eradicating it) will lose power and market share under trump admin. VP JD Vance mentioned this ideology on Rogan’s podcast. let’s see how it plays out if RFK or Casey Means run the FDA. things that are almost certain under trump admin is tighter food regulations (bans on artificial colors, crackdown on regulatory capture by multinational food conglomerates) as well as banning mandates for pediatric vaccination. πŸ’‰

User Image NoRisksNoFun Posted - 2 weeks ago

$BEAM scd therapy , to many companies and treatment possibilities for small market size

User Image Mdpnc777 Posted - 2 weeks ago

$BEAM Data is best in class for the Beacon trial. This is going to soar. Hemoglobin levels looking extremely good for patients.

User Image Jchoi0507 Posted - 2 weeks ago

$BEAM

User Image CelticBeast Posted - 2 weeks ago

$BEAM time to shine!!!!!!πŸ™πŸ»πŸ€

User Image BernhardtA19 Posted - 2 weeks ago

@777Dog Both $EDIT and $BEAM use conditioning chemotherapy to make space in bone marrow for the edited stem cells. Trial investigators and the FDA (maybe?) said that the chemo killed the patient in the $BEAM trial. Same could happen with $EDIT, it seems. That’s why $BEAM came out swinging by mentioning its ESCAPE efforts which sidestep the toxicity of chemo in the BEAM-101 trail.

Analyst Ratings
RBC Capital Sector Perform Sep 19, 24
Jones Trading Hold Sep 17, 24
Stifel Buy Sep 11, 24
HC Wainwright & Co. Buy Aug 22, 24
JP Morgan Overweight Aug 7, 24
Barclays Equal-Weight Aug 7, 24
RBC Capital Sector Perform Aug 7, 24
HC Wainwright & Co. Buy Jul 23, 24
Barclays Equal-Weight May 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Simon Amy Chief Medical Office.. Chief Medical Officer Jul 10 Sell 30.48 391 11,918 68,917 08/09/23
Ciaramella Giuseppe President and CSO President and CSO Jul 21 Sell 32.04 156,530 5,015,221 48,250 07/25/23
Ciaramella Giuseppe President and CSO President and CSO Jul 21 Option 7.22 92,490 667,778 49,456 07/25/23
Evans John M. CEO CEO Apr 03 Sell 29.7 11,654 346,124 1,117,979 04/05/23
Ciaramella Giuseppe President & CSO President & CSO Apr 03 Sell 29.7 3,672 109,058 112,290 04/05/23
Bellon Christine Chief Legal Officer Chief Legal Officer Apr 03 Sell 29.7 2,092 62,132 82,790 04/05/23
Simon Amy Chief Medical Office.. Chief Medical Officer Apr 03 Sell 29.72 16,099 478,462 69,308 04/05/23
Burrell Terry-Ann Chief Financial Offi.. Chief Financial Officer Apr 03 Sell 29.7 4,640 137,808 47,117 04/05/23
Bellon Christine Chief Legal Officer Chief Legal Officer Mar 30 Option 7.22 8,941 64,554 67,382 03/31/23
Evans John M. CEO CEO Jan 31 Option 7.22 13,850 99,997 1,129,153 03/31/23
Burrell Terry-Ann Chief Financial Offi.. Chief Financial Officer Jan 23 Sell 45.02 20,236 911,025 31,277 01/25/23
Burrell Terry-Ann Chief Financial Offi.. Chief Financial Officer Jan 23 Option 13.68 20,236 276,828 46,087 01/25/23
Ciaramella Giuseppe President & CSO President & CSO Dec 12 Option 2.45 26,863 65,814 142,477 12/14/22
Ciaramella Giuseppe President & CSO President & CSO Dec 12 Sell 43.11 51,015 2,199,257 91,462 12/14/22
FMR LLC 10% Owner 10% Owner Sep 06 Sell 54.25 551 29,892 09/08/22
FMR LLC 10% Owner 10% Owner Aug 04 Sell 60.75 20,326 1,234,804 08/08/22
Evans John M. CEO CEO Apr 28 Option 4.13 59,450 245,528 1,148,520 05/02/22
Evans John M. CEO CEO Apr 28 Sell 38.68 50,000 1,934,000 143,000 05/02/22
FMR LLC 10% Owner 10% Owner Apr 12 Sell 50.57 19,466 984,396 04/14/22
Ciaramella Giuseppe President & CSO President & CSO Mar 31 Sell 59.11 1,859 109,885 115,614 04/04/22
Evans John M. CEO CEO Mar 31 Sell 59.11 6,261 370,088 1,089,070 04/04/22
Burrell Terry-Ann CFO CFO Mar 31 Sell 59.11 1,787 105,630 38,278 04/04/22
Evans John M. CEO CEO Jan 31 Option 1.03 100,000 103,000 1,038,825 02/02/22
Evans John M. CEO CEO Jan 31 Sell 65.95 50,000 3,297,500 163,000 02/02/22
Ciaramella Giuseppe President & CSO President & CSO Dec 20 Option 7.22 29,393 212,217 87,877 12/22/21
Ciaramella Giuseppe President & CSO President & CSO Dec 20 Sell 85.62 29,393 2,516,629 62,773 12/22/21
Ciaramella Giuseppe President & CSO President & CSO Apr 02 Option 0.67 4,030 2,700 19,761 04/02/21
Ciaramella Giuseppe President & CSO President & CSO Jan 04 Option 0.85 55,842 47,466 15,731 01/04/21
Ciaramella Giuseppe President & CSO President & CSO Jan 04 Sell 84.14 43,842 3,688,866 3,731 01/04/21
Evans John M. CEO CEO Jan 04 Sell 85.39 22,300 1,904,197 970,957 01/04/21